Cargando…

153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro

BACKGROUND: Molnupiravir is an orally available prodrug of the antiviral nucleoside analog N-Hydroxycytidine (NHC). In preclinical studies NHC has shown broad-spectrum antiviral activity against multiple RNA viruses including SARS-CoV-2. Incorporation of NHC by viral polymerases impairs replication...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strizki, Julie, Murgolo, Nicholas, Gaspar, John, Howe, John, Hutchins, Beth, Mohri, Hiroshi, Ho, David D, Hazuda, Daria, Grobler, Jay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752128/ http://dx.doi.org/10.1093/ofid/ofac492.231

Ejemplares similares

543. Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical Studies
por: Grobler, Jay, et al.
Publicado: (2021)

511. Treatment with Molnupiravir in the MOVe-In and MOVe-Out Clinical Trials Results in an Increase in Transition Mutations Across the SARS-CoV-2 Genome
por: Strizki, Julie, et al.
Publicado: (2021)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021)

Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
por: Johnson, Matthew G., et al.
Publicado: (2023)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Letter to the Editor in Response to Zhou et al
por: Troth, Sean, et al.
Publicado: (2021)

Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro
por: Huang, Zi-Xin, et al.
Publicado: (2023)

In vitro and in vivo efficacy of Molnupiravir against Zika virus infections
por: Wang, Zhuang, et al.
Publicado: (2023)

Publisher Correction: Molnupiravir: coding for catastrophe
por: Malone, Brandon, et al.
Publicado: (2021)

Molnupiravir, une affaire franco-européenne
por: Manus, Jean-Marie
Publicado: (2021)

Molnupiravir: From Hope to Epic Fail?
por: Focosi, Daniele
Publicado: (2022)

Why Molnupiravir Fails in Hospitalized Patients
por: Brown, Ashley N., et al.
Publicado: (2022)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Molnupiravir; molecular and functional descriptors of mitochondrial safety
por: Wallace, K.B., et al.
Publicado: (2022)

Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)

Concise two-step chemical synthesis of molnupiravir
por: Pereira, Vinícius R. D., et al.
Publicado: (2022)

The Organon, Section 153
por: Wells, P. P.
Publicado: (1881)

The Organon, Section 153
por: Fitz, W. H. A.
Publicado: (1888)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023)

In vivo and in vitro exposure to PCB 153 reduces long-term potentiation.
por: Hussain, R J, et al.
Publicado: (2000)

Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates
por: Asante-Appiah, Ernest, et al.
Publicado: (2021)

Molnupiravir in COVID-19: A systematic review of literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

What will be the role of molnupiravir in the treatment of COVID-19 infection?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Molnupiravir and Its Antiviral Activity Against COVID-19
por: Tian, Lili, et al.
Publicado: (2022)

Molnupiravir: A new candidate for COVID‐19 treatment
por: Pourkarim, Fariba, et al.
Publicado: (2021)

Vascularite rétinienne post-Covid-19 et Molnupiravir
por: Lassouli, I., et al.
Publicado: (2022)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
por: Yip, Ashley Jia Wen, et al.
Publicado: (2022)

PANORAMIC: important insights into molnupiravir use in COVID-19
por: Kidd, Michael R, et al.
Publicado: (2023)

Healthcare worker access to molnupiravir: A case series
por: O’Keeffe, Jessica C., et al.
Publicado: (2023)

The decay of /sup 153/Ho to the transitional N=87 nucleus /sup 153/Dy
por: Paris, P, et al.
Publicado: (1981)

153rd LHCC Meeting
Publicado: (2023)

Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat
por: Chang, Chun-Hao, et al.
Publicado: (2023)

Inhibitors of human immunodeficiency virus type I
por: Hazuda, Daria J
Publicado: (2006)

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
por: Kabinger, Florian, et al.
Publicado: (2021)

Decoding molnupiravir-induced mutagenesis in SARS-CoV-2
por: Menéndez-Arias, Luis
Publicado: (2021)

NZ's Pharmac negotiates deal for molnupiravir to treat COVID-19
Publicado: (2021)

Merck says molnupiravir has favourable benefit-risk assessment
Publicado: (2021)

Making Statistical Sense of the Molnupiravir MOVe-OUT Clinical Trial
por: Thorlund, Kristian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_etbn6docgih0iv0au9saunbaip